The q-t interval and antimuscarinic drugs

Current Urology Reports

Volumn 6, Issue 6, 2005, Pages 405-409

  Dmochowski, Roger ^a   Staskin, David R ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Moxifloxacin; Overactive Bladder; Oxybutynin; Terfenadine; Tolterodine

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART RATE; HUMAN; LONG QT SYNDROME; PHYSIOLOGY; REVIEW; URINE INCONTINENCE;

ELECTROPHYSIOLOGY; HEART RATE; HUMANS; LONG QT SYNDROME; MUSCARINIC ANTAGONISTS; URINARY INCONTINENCE;

EID: 33646722732     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-005-0033-2     Document Type: Article

References (20)

1. Roden DM: Drug-induced prolongation of the Q-T interval. N Engl J Med 2004, 350:1013–1022. Excellent review of the status of drug induction of Q-T phenomena and the current status of same. DOI: 10.1056/NEJMra032426
2. Langtree HD, McTavish D: Terodiline: a review of its pharmacological properties and therapeutic use in the treatment of urinary incontinence. Drugs 1990, 40:748–761.
3. Stewart DA, Taylor J, Gosh S, et al.: Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992, 42:577–580. DOI: 10.1007/BF00265918
4. Thomas SHL, Higham PD, Hartigan-Go K, et al.: Concentration-dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 1995, 74:53–56. Analysis correlating cardiac side events with the magnitude of serum levels.
5. McCloud AA, Thorogood S, Barnett S: Torsade de pointes complicating treatment with terodiline. BMJ 1991, 302:1469.
6. Connolly MJ, Astrige PG, White EG, et al.: Torsade de pointes ventricular tachycardia and terodiline. Lancet 1991, 338:344–345. DOI: 10.1016/0140-6736(91)90481-4
7. Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long Q-T syndrome: clinical impact. Circulation 1999, 99:529–534. Consideration of the relationship between genetic constitution and development of overt cardiac dysrhythmias associated with the long Q-T syndrome.
8. Thompson D, Oster G: Use of terfenadine and contraindicated drugs. JAMA 1996, 275:1339–1341. DOI: 10.1001/jama.275.17.1339
9. Scarpero HS, Dmochowski RR: Muscarinic receptors and the urinary bladder. Curr Urol Rep 2004, 4:421–428. DOI: 10.1007/s11934-003-0021-3
10. Bannerjee S, Routledge Pa, Pugh S, et al.: Poisoning with oxybutynin. Hum Exp Toxicol 1991, 10:225–226. DOI: 10.1177/096032719101000313
11. Wang PS, Levin R, Zhao S, Avorn J: Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. J Am Geriatr Soc 2002, 50:117–124. Epidemiologic analysis of medication ingestion and cardiac events, considering the antimuscarinics, antihistamines, and concomitant administration of drugs with hepatic cytochrome activity. DOI: 10.1046/j.1532-5415.2002.50017.x
12. Kang J, Chen XL, Wang H, et al.: Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 2005, 308:935–940. DOI: 10.1124/jpet.103.062182
13. Jones SE, Shuba LM, Zhabyeyev P, et al.: Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials. Br J Pharmacol 2000, 131:245–254. DOI: 10.1038/sj.bjp.0703595
14. Hussain RM, Hartigan-Go K, Thomas SH, et al.: Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996, 41:73–75.
15. Jones SE, Kasamaki Y, Shuba LM, et al.: Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 2000, 35:334–340. DOI: 10.1097/00005344-200002000-00024
16. Appell RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50(suppl 6A):90–96. Review of all of the clinical safety information associated with tolterodine. DOI: 10.1016/S0090-4295(97)00599-2
17. Enablex Prescribing Information. http//www. novartis.com. Accessed August 19, 2005.
18. Vesicare Prescribing Information. http//www.astellis.com. Accessed August 19, 2005.
19. Ikeda K, Kobayashi S, Suzuki M, et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:97–103. DOI: 10.1007/s00210-002-0554-x
20. Sanctura Prescribing Information. http//www.indevus.com. Accessed August 19, 2005.